Learn how our renal genetic testing was developed by a team of experts and is among the most comprehensive diagnostic testing available.
Renal Pathology at Mayo Clinic Laboratories
Mayo Clinic Laboratories’ is integrated with the Renal Biopsy Laboratory in the Department of Laboratory Medicine and Pathology at Mayo Clinic. Board-certified pathologist have a special interest in non-neoplastic disease of the kidney and...
Frequently asked questions - Insights
Check out the answers to the most frequently asked questions about pharmacogenomic testing at Mayo Clinic Laboratories.
Carbohydrate metabolism - Insights
Learn more about how Mayo Clinic Laboratories testing for carbohydrate metabolism can identify genetic variants and confirm diagnosis of these complex conditions.
Biopharma only testing - Insights
Find out how our suite of BioPharma Diagnostics-specific neurology testing can provide answers for your patients.
Precision oncology therapeutics - Insights
Learn more about our personalized cancer testing that establishes patients’ genetic profiles and allows physicians to select medications that optimize therapeutic efficacy while minimizing harmful reactions.
Whole genome sequencing - Insights
Check out Mayo Clinic Laboratories’ whole genome testing, a next-generation sequencing assay that interrogates nearly every base pair of an individual’s DNA, including the mitochondrial genome.
Delta Health: Confronting a global pandemic in rural Colorado - Insights
Delta Health leveraged their relationship with Mayo Clinic Laboratories to support patient in rural Colorado during the COVID-19 pandemic. Delta Health and Mayo Clinic Laboratories have collaborated for over 17 years to perform complex and...
Reversing a dire disorder: Lorinda McKinley - Insights
Advanced testing at Mayo Clinic Laboratories that confirmed a diagnosis of myasthenia gravis put Lorinda McKinley on the road to renewed health after she nearly lost it all to the rare autoimmune disease.
Our pharmacogenomics (PGx) testing, which is used to inform medication selection and dosing, has the potential to revolutionize medication selection for individuals with treatment-resistant depression.